Minodronate approved for osteoporosis in Japan
This article was originally published in Scrip
Executive Summary
Astellasand Ono's oral bisphosphonate Bonoteo/Recalbon (minodronate (minodronic acid hydrate)) has been approved in Japan for the treatment of osteoporosis. The clearance, which follows a positive recommendation in October, is the first worldwide for the once-daily therapy.